Research programme: anticancer phenylarsonic acid derivatives - Parker HughesAlternative Names: anticancer phenylarsonic acid derivatives research programme - Parker Hughes
Latest Information Update: 25 Aug 2006
At a glance
- Originator Parker Hughes Institute
- Mechanism of Action Apoptosis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 25 Aug 2006 No development reported - Preclinical for Cancer in USA (unspecified route)
- 01 Aug 2003 Preclinical trials in Cancer in USA (unspecified route)